Stay updated with breaking news from Director Eric. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biogen (NASDAQ:BIIB – Get Free Report) had its price objective cut by research analysts at UBS Group from $250.00 to $214.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s price objective indicates a potential upside of 11.37% from the stock’s […]
Biogen (NASDAQ:BIIB – Get Free Report) had its price objective reduced by analysts at UBS Group from $250.00 to $214.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s price objective points to a potential upside of 11.37% from the […]
Flputnam Investment Management Co. reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 8.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,931 shares of the biotechnology company’s stock after selling 185 shares during the […]
Flputnam Investment Management Co. decreased its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 8.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,931 shares of the biotechnology company’s stock after selling 185 shares during the […]
Tobam reduced its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 7.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,922 shares of the biotechnology company’s stock after selling 933 shares during the quarter. Tobam’s holdings in Biogen were worth […]